Genefitletics
Genefitletics is a New Delhi-based TechBio company that combines multi-omics, biophysics and machine learning in its Bioelectome Platform to deliver early diagnostic tests for degenerative diseases and oral cancer through B2B partnerships with healthcare providers.
- Company typePrivate
- Founded2019
- HeadquartersNew Delhi, India
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Genefitletics does
Genefitletics is a privately-held TechBio company headquartered in New Delhi, India, founded in 2019 and operating with 1-10 employees. The company has built the "Bioelectome Platform," a computational system combining multi-omics (gut and oral microbiome, mitochondrial function, cytokine signaling), biophysics and machine learning to model microbiome-mitochondria crosstalk and the bioelectric communication network of cells. The platform integrates insights from over 35,000 scientific papers and 8 internal validation studies, and underpins two commercially available diagnostic tests: OraHyg (early detection of degenerative diseases including Type 2 Diabetes, cardiovascular disease, chronic kidney disease, IBD, and gum diseases) and OraOnco (early-stage oral cancer detection).
The company operates a B2B enterprise sales motion rather than direct-to-consumer, targeting longevity clinics, hospitals, healthcare practitioners, diagnostic testing companies, DNA testing companies and functional medicine specialists across a regional (India-centric) footprint. Its stated revenue streams comprise diagnostic testing services delivered on a subscription/recurring basis through partner clinics, plus a planned brand of precision biotics on a one-time license model; pricing is not publicly disclosed.
Genefitletics is capital-constrained at the pre-seed stage — a single April 2023 round closed at a Rs 7.5 crore valuation with no disclosed institutional investors, and no subsequent funding rounds, revenue figures, customer counts or milestones are publicly available. The company has not yet disclosed any patents, regulatory certifications, named B2B customer logos, management team details or senior AI/ML hires, and there is no evidence of partnerships beyond the generic onboarding motion described on its website.
Genefitletics firmographics
Firmographics- Name
- Genefitletics
- Legal name
- Genefitletics
- Website
- https://genefitletics.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Genefitletics is a New Delhi-based TechBio company that combines multi-omics, biophysics and machine learning in its Bioelectome Platform to deliver early diagnostic tests for degenerative diseases and oral cancer through B2B partnerships with healthcare providers.
- Ownership category
- akta.pro rank
Genefitletics industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)
- akta.pro secondary industries
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Transcriptomics & Gene Expression Profiling Services (HLAGANAE)
Keywords
Where Genefitletics is headquartered
LocationHeadquarters
- HQ city
- New Delhi
- HQ country
- India
- HQ region
- Asia
Markets served
Genefitletics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Precision Biotics Brand: The company intends to use pre-seed funds to develop oral microbiome and human gene expression tests and launch its own brand of precision biotics.
- Diagnostic Testing Services: Early detection tests for degenerative diseases and cancer offered through B2B partnerships with healthcare providers.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Genefitletics product offering
Product offeringCore offering
Genefitletics sells the Bioelectome Platform and its associated diagnostic tests (OraHyg for degenerative diseases and OraOnco for oral cancer), which use multi-omics, biophysics, and machine learning to analyze microbiome–mitochondria crosstalk. Tests are offered through B2B partnerships with healthcare providers (longevity clinics, hospitals, diagnostic and DNA testing companies, functional medicine specialists) for early-stage disease detection and regenerative therapeutic interventions.
Product overview
Genefitletics offers a tech-bio platform consisting of the core Bioelectome Platform and two diagnostic tests (OraHyg for degenerative diseases and OraOnco for cancer). The platform integrates multi-omics, biophysics, and machine learning to measure the bioelectric communication network between the microbiome and mitochondria, enabling early disease detection and regenerative therapeutic interventions.
Differentiator
Problem solved
Functional benefit
Brands
- OraHyg: Precision diagnostics test for degenerative diseases including Type 2 Diabetes, Cardiovascular Diseases, Chronic Kidney Disease, IBD, and Gum Diseases
- OraOnco
Products and services
- OraHyg A precision diagnostics test that measures oral microbiome functions, metabolites, and their downstream systemic health impacts to enable early-stage detection of Type 2 Diabetes, Cardiovascular Diseases, Chronic Kidney Disease, IBD, and Gum Diseases. Sold through B2B healthcare provider partnerships.
- OraOnco A precision diagnostics test that analyzes oral microbiome functions and their downstream impact to enable early-stage detection of oral cancer. Sold through B2B healthcare provider partnerships.
Quantifiable outcome
- 8 internal validation studies completed
- +2 more outcomes
Companies that use Genefitletics
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles1 record
Genefitletics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Genefitletics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- Longevity ClinicscoreB2B partnerships with longevity clinics looking to incorporate early disease diagnostics in their clinical practices using the Bioelectome Platform.
- HospitalscorePartnerships with hospitals for early disease diagnostics integration using the microbiome-mitochondria crosstalk platform.
- Healthcare PractitionerscorePartnerships with healthcare practitioners for incorporating early disease diagnostics in clinical practices using biophysics and machine learning platform.
- Diagnostic Testing CompaniescorePartnerships with diagnostic testing companies for integration of microbiome and gene expression tests into their testing portfolios.
- DNA Testing CompaniescorePartnerships with DNA testing companies to enhance their services with microbiome-mitochondria analysis and early disease detection capabilities.
- Functional Medicine SpecialistscorePartnerships with functional medicine specialists for incorporating regenerative therapeutics and early disease diagnostics in their practice.
Scale indicators4 records
Recent moves5 records
Expansion highlights4 records
Genefitletics competitors and assessment
Company assessmentDirect peers
- ZOE: ZOE combines microbiome testing with metabolic and blood biomarkers to deliver personalized health scores. Comparable to Genefitletics in using multi-modal biological data plus ML to drive early health interventions.
- Viome: Viome offers gut microbiome-based diagnostic tests with AI-driven personalized nutrition recommendations. Directly comparable to Genefitletics in combining microbiome analysis with machine learning and consumer/B2B-facing health insights.
- Thryve: Thryve (formerly Thryve Inside) offers gut microbiome testing and white-label microbiome analytics for health and wellness brands. Comparable in microbiome diagnostics and B2B white-label/API distribution to health partners.
- Carbiotix: Carbiotix provides microbiome testing services and prebiotic therapeutics. Comparable to Genefitletics in offering microbiome diagnostics alongside an associated therapeutic/consumable product line.
- Sun Genomics: Sun Genomics offers personalized gut microbiome testing with custom probiotic formulations. Directly comparable to Genefitletics in combining microbiome diagnostics with personalized therapeutic recommendations.
- DayTwo: DayTwo provides gut microbiome-based personalized nutrition for glycemic control. Directly comparable in microbiome diagnostics, ML-driven recommendations, and B2B health-partner distribution.
Broad incumbents
- Human Longevity Inc. HLI offers comprehensive whole-genome, microbiome, and metabolomics-based health assessments. Comparable as a broader incumbent in the longevity/preventive diagnostics category Genefitletics targets.
- Guardant Health: Guardant Health is an established precision oncology diagnostics company using liquid biopsy and genomics. Comparable as a broad incumbent demonstrating the commercial scale potential of molecular diagnostics platforms serving clinicians.
Regional players
- Mapmygenome: India-based genomics and molecular diagnostics company offering preventive health and personalized medicine tests. Comparable as a regional peer in multi-omics preventive diagnostics targeting Indian clinicians and consumers.
- Bione: India-based microbiome and genetic testing company. Comparable as a South Asian microbiome diagnostics peer addressing similar consumer and clinician segments in Genefitletics' home geography.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Genefitletics social profiles
Digital presenceGenefitletics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genefitletics leadership team
Management profileNumber of profiles
Genefitletics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genefitletics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genefitletics
What does Genefitletics do?
Genefitletics sells the Bioelectome Platform and its associated diagnostic tests (OraHyg for degenerative diseases and OraOnco for oral cancer), which use multi-omics, biophysics, and machine learning to analyze microbiome–mitochondria crosstalk. Tests are offered through B2B partnerships with healthcare providers (longevity clinics, hospitals, diagnostic and DNA testing companies, functional medicine specialists) for early-stage disease detection and regenerative therapeutic interventions.
Is Genefitletics a public or private company?
Genefitletics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Genefitletics founded?
Genefitletics was founded in 2019. It employs 1 to 10 people.
Where is Genefitletics based?
Genefitletics is headquartered in New Delhi, India, in the Asia region.
How does Genefitletics make money?
Two revenue lines are on record. Precision Biotics Brand is the primary driver. The others are diagnostic Testing Services.
Who are Genefitletics's main competitors?
Direct peers on record are ZOE, Viome, Thryve, Carbiotix, Sun Genomics and DayTwo. Broad incumbents are Human Longevity Inc. and Guardant Health. Regional players are Mapmygenome and Bione.
Does Genefitletics have an API?
No public API is recorded for Genefitletics.
What industry is Genefitletics in?
Genefitletics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 541714 and its SIC code is 2835.